OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sharma on the Rationale to Combine Veliparib With Chemotherapy in TNBC

August 31st 2020

Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Dr. Grothey on Biomarkers to Inform Metastatic CRC Treatment Decisions

August 31st 2020

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Dr. Richter on the Utility of Isatuximab in Relapsed/Refractory Myeloma

August 31st 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Dr. Dimopoulos on the Goal of the ASPEN Trial in Waldenström Macroglobulinemia

August 29th 2020

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.

Dr. Daver on the Tolerability of Magrolimab Plus Azacitidine in AML/MDS

August 29th 2020

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Dr. Weitzel on the Identification of Li-Fraumeni Syndrome

August 28th 2020

Jeffery Weitzel, MD, discusses the identification of Li-Fraumeni syndrome.

Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma

August 28th 2020

Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600–mutant melanoma.

Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid Tumors

August 28th 2020

Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.

Dr. Serrano on the Rationale for the INVICTUS Trial in Advanced GIST

August 28th 2020

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Dr. Li on the Subgroup Analysis of the IMbrave150 Trial in Older Patients With HCC

August 28th 2020

Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular carcinoma.

Dr. Pegram on the DESTINY-Breast01 Trial With Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

August 27th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.

Dr. Pennell on the Evolution of Targeted Treatment in NSCLC

August 27th 2020

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Dr. Garon on the Role of Trastuzumab Deruxtecan in Lung Cancer

August 27th 2020

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon Cancer

August 27th 2020

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

August 27th 2020

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Dr. Pant on Targeting KRAS Mutations in Metastatic Solid Tumors

August 27th 2020

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Dr. Brufsky on Treatment Approaches for Early-Stage HER2+ Breast Cancer

August 27th 2020

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

Dr. Gradishar on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

August 27th 2020

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.